Precision medicine to treat Alzheimer’s: Results of a study using a whole-systems wellness approach
Standard pharmaceutical interventions for Alzheimer’s disease have thus far proven to be insufficient, with over 400 clinical trials to date being deemed unsuccessful and going unapproved1. Certain pharmaco-therapies like memantine or donanemab offered a delay in symptom progression but never offered any reversal of symptoms or treatment of pathology2.